Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong
Samsung Biologics reported 11% YoY revenue growth in 4Q23, driven by Plant 4 operations and strong sales backlog. Resilient business performance...
421 Views
HK CEO & Director Dealings (26 Jan 2024): Sun Hung Kai, Wuxi Bio, Sichuan Kelun-Bio, Wisdom Sports
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...
509 Views
Hong Kong Connect Flows (Jan 19th): CCB
We analyzed southbound Hong Kong connect flows in the past week and highlight southbound Hong Kong connect flows for CCB.
459 Views
HK Short Interest Weekly: Citic Sec
We analyzed the latest HK SFC report for aggregate short position as of Jan 12th and highlight short interest changes in Citic Sec.
347 Views
WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?
WuXi XDC's share price rebounded quickly after a brief correction. Considering that a certain part of WuXi Bio's significant increase in new orders...
930 Views